Research classification: Human clinical trials
Compound overview
Retatrutide (LY3437943) is an investigational peptide studied as an agonist at GLP-1, GIP, and glucagon receptors.
Published research
A published randomized phase 2 trial investigated retatrutide in adults with obesity and reported changes in body weight along with adverse events. Those observations concern the sponsor's investigational pharmaceutical formulation and study conditions, not separately supplied research vials.
Evidence limitations
Clinical outcomes cannot be attributed to any APEP Biolabs preparation. Published data do not verify the identity, content, sterility, safety, or efficacy of another manufacturer's material.
Primary publications and technical references
Literature summaries are educational and refer only to the specific preparations and methods studied by the cited authors. These publications do not demonstrate that any APEP Biolabs material is suitable for human or veterinary use. Not medical advice. Laboratory research only. Do not administer or consume research materials.